Mesoblast Stock Gains 10%
· rttnews.com
Mesoblast Limited (MESO) shares rose $1.54, or 9.91 percent, to $17.14 on Monday, possibly following the company's announcement that it had completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain.
Mesoblast Limited (MESO) shares rose $1.54, or 9.91 percent, to $17.14 on Monday, possibly following the company's announcement that it had completed patient tr...